Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents

Abstract

A series of 4H-chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylates derivatives were synthesized via a three component one-pot condensation of chromone-3-carbaldehyde, alkyl acetoacetate, and urea or thiourea, using MCM-41-SOH as efficient nanocatalysts and evaluated for their anticancer activity using a combined in silico docking and molecular dynamics protocol to estimate the binding affinity of the title compounds with the Bcr-Abl oncogene. Two programs, AutoDock 4 and AutoDock Vina software were applied to dock the target protein with synthesized compounds and ATP. AutoDock runs resulted in binding energy scores from -7.8 to -10.16 kcal/mol for AutoDock 4 and -6.9 to -8.5 (kcal/mol) for AutoDock Vina. Furthermore, molecular dynamics (MD) simulations are performed using Gromacs for up to 20 ns simulation time investigating the stability of a ligand-protein complex. Finally, a theoretical experiment using MD simulation for 10 ns was performed without defining the initial coordinates, and the affinity binding of ligand to receptors was directly studied, which revealed that the ligand approaches the active sites. The relative free binding energy for the structure 06 (S06), which has the highest binding energy in Autodock 4 and Autodock Vina (-10.10 and -8.5 kcal/mol, respectively), was also evaluated by molecular mechanics (MM) with Poisson-Boltzmann (PB) and a surface area solvation (MM-PBSA) method using g_mmpbsa tools for the last 15 ns MD. On the basis of binding energy scores, a negative binding energy value of 73.6 kcal/mol, S06, was recognized as the dominant potential inhibitors. The cytotoxic properties of S06 was evaluated against three cell lines, acute T cell leukemia (Jurkat), human chronic myelogenous leukemia, (K562) and human foreskin fibroblast (Hu02) using the microculture tetrazolium test MTT assay. Cisplatin was used as the reference agent. The results indicated that S06 has a higher safety index (SI = 0.73, IC50 = 152.64 μg/mL for Jurkat and IC50 = 110.25 μg/mL for Hu02, P < 0.05 means ± SD for four independent experiments) compared to cisplatin (SI = 0.56, IC50 = 8.86 μg/mL for Jurkat and IC50 = 4.96 μg/mL for Hu02). The in silico results indicated that the proposed structures, which have no toxic effects, are potential tyrosine kinase inhibitors (TKIs) that target Bcr-Abl and thus prevent uncontrolled cell growth (proliferation) but not necessarily cell death (apoptosis) and might potentially constitute an interesting novel class of targeted antileukemic drugs, which deserve further studies.

Are Losartan and Imatinib Effective Against SARS-CoV2 Pathogenesis? a Pathophysiologic-Based in Silico Study

“…Through redocking, the binding energies and the binding status of the small molecules with the protein structures was evaluated. 80 Analysis RMSD, RMSF, hydrogen bonding and radius of gyration diagrams exported after performing MD simulation were analyzed by qtgrace. 81 Ligplot 82 and poseview 83 were used for determining the hydrogen bonding, hydrophobic and pi-pi interactions after docking and MD simulation.…”

Computational Insight into Protein Tyrosine Phosphatase 1B Inhibition: A Case Study of the Combined Ligand- and Structure-Based Approach

“…Meanwhile, these ligands were used to conduct native docking to measure the docking conformations. Four different docking programs—AutoDock, AutoDock Vina [ 27 ], SP Glide [ 24 , 28 ], and XP Glide [ 29 , 30 ]—were used for improving the accuracy of prediction. Then, Xscore followed by molecular docking was reliable and accurate for forecasting protein-ligand binding free energies ( Table 3 ).…”

Searching for new cytotoxic agents based on chromen-4-one and chromane-2,4-dione scaffolds

“…They have been suggested to exert their effect via inhibition of topoisomerase enzymes (7820). An in silico study has shown that 4H-chromone-1,2,3,4-tetrahydropyrimidine -5-carboxylates derivatives could be inhibitors of Bcr-Abl tyrosine kinase, which has important oncogenic functions in certain types of leukemia (27). Another investigation on breast and lung cancer cells has demonstrated that sulfonamide containing chromone derivatives possess inhibitory activity against carbonic anhydrase IX and XII, two important targets in certain types of cancer (29).…”

“…The anticancer effect of these compounds has been reported against leukemia (222527) and breast cancer cells (202829). Furthermore, chromones seem also to exert antiproliferative effects against lung and colon cancer cells (8).…”